Jack Scannell, PhD

Jack Scannell has researched biomedical R&D productivity from financial, regulatory, and scientific perspectives, focusing on the contrast between cheaper and better scientific inputs, and the long-term decline in R&D output efficiency. He is now the CEO of Etheros Pharmaceuticals, a pre-clinical stage company that is developing new chemistries for neurodegenerative diseases. He is Associate of the Innogen Institute and of the Department of Science, Technology, and Innovation Studies at the University of Edinburgh. He had senior roles in drug and biotech investment at UBS and at Sanford Bernstein. He was Head of Discovery Research at e-Therapeutics PLC, an Oxford-based biotechnology firm.. He has a PhD in Physiology from Oxford University and a degree in Medical Sciences from Cambridge University.

12.11.2020   What people get wrong about economics of the drug industry 
  Video | Slides
16.06.2022 Predictive validity in drug discovery: what it is, why it matters and how to improve it
   Video | Slides | Transcript
10.11.2022 The waste in futile oncology drug development
   Video | Slides | Transcript
 January 18, 2024  Cancer bioscience: too focused on drug discovery?